204 related articles for article (PubMed ID: 19003543)
1. Conivaptan for hyponatremia in the neurocritical care unit.
Wright WL; Asbury WH; Gilmore JL; Samuels OB
Neurocrit Care; 2009; 11(1):6-13. PubMed ID: 19003543
[TBL] [Abstract][Full Text] [Related]
2. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit.
Murphy T; Dhar R; Diringer M
Neurocrit Care; 2009; 11(1):14-9. PubMed ID: 19123060
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.
Annane D; Decaux G; Smith N;
Am J Med Sci; 2009 Jan; 337(1):28-36. PubMed ID: 19057376
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
Der-Nigoghossian C; Lesch C; Berger K
Pharmacotherapy; 2017 May; 37(5):528-534. PubMed ID: 28295447
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
Ghali JK; Koren MJ; Taylor JR; Brooks-Asplund E; Fan K; Long WA; Smith N
J Clin Endocrinol Metab; 2006 Jun; 91(6):2145-52. PubMed ID: 16522696
[TBL] [Abstract][Full Text] [Related]
7. Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion.
Potts MB; DeGiacomo AF; Deragopian L; Blevins LS
Neurosurgery; 2011 Aug; 69(2):268-73. PubMed ID: 21792136
[TBL] [Abstract][Full Text] [Related]
8. Use of conivaptan for management of hyponatremia following surgery for Cushing's disease.
Breshears JD; Jiang B; Rowland NC; Kunwar S; Blevins LS
Clin Neurol Neurosurg; 2013 Nov; 115(11):2358-61. PubMed ID: 24041963
[TBL] [Abstract][Full Text] [Related]
9. Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia--efficacy, safety, and pharmacokinetics.
Palmer BF; Rock AD; Woodward EJ
Drug Des Devel Ther; 2016; 10():339-51. PubMed ID: 26848258
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.
Koren MJ; Hamad A; Klasen S; Abeyratne A; McNutt BE; Kalra S
Am J Health Syst Pharm; 2011 May; 68(9):818-27. PubMed ID: 21515866
[TBL] [Abstract][Full Text] [Related]
11. Use of Conivaptan (Vaprisol) for hyponatremic neuro-ICU patients.
Naidech AM; Paparello J; Liebling SM; Bassin SL; Levasseur K; Alberts MJ; Bernstein RA; Muro K
Neurocrit Care; 2010 Aug; 13(1):57-61. PubMed ID: 20568023
[TBL] [Abstract][Full Text] [Related]
12. Observations regarding the use of the aquaretic agent conivaptan for treatment of hyponatremia.
Metzger BL; DeVita MV; Michelis MF
Int Urol Nephrol; 2008; 40(3):725-30. PubMed ID: 18363040
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of conivaptan bolus dosing in hyponatremic neurosurgical patients.
Marik PE; Rivera R
Pharmacotherapy; 2013 Jan; 33(1):51-5. PubMed ID: 23307545
[TBL] [Abstract][Full Text] [Related]
14. Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury.
Galton C; Deem S; Yanez ND; Souter M; Chesnut R; Dagal A; Treggiari M
Neurocrit Care; 2011 Jun; 14(3):354-60. PubMed ID: 21409494
[TBL] [Abstract][Full Text] [Related]
15. Intravenous conivaptan.
Moen MD; Keating GM
Am J Cardiovasc Drugs; 2008; 8(5):341-8; discussion 349. PubMed ID: 18828645
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of 3% saline vs. conivaptan in achieving hyponatremia treatment goals.
Dominguez M; Perez JA; Patel CB
Methodist Debakey Cardiovasc J; 2013; 9(1):49-53. PubMed ID: 23519387
[TBL] [Abstract][Full Text] [Related]
18. Conivaptan for treatment of hyponatremia in neurologic and neurosurgical adults.
Buckley MS; Patel SA; Hattrup AE; Kazem NH; Jacobs SC; Culver MA
Ann Pharmacother; 2013 Sep; 47(9):1194-200. PubMed ID: 24259735
[TBL] [Abstract][Full Text] [Related]
19. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia.
Kalra S; Efrati S; Arthur JM; Oliven A; Velez JC; McNutt BE; Klasen S; Abeyratne A
Am J Health Syst Pharm; 2011 Apr; 68(7):590-8. PubMed ID: 21411800
[TBL] [Abstract][Full Text] [Related]
20. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
Wada K; Matsukawa U; Fujimori A; Arai Y; Sudoh K; Sasamata M; Miyata K
Biol Pharm Bull; 2007 Jan; 30(1):91-5. PubMed ID: 17202666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
